Compare Amylx Pharmaceuticals Inc (AMLX) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Autozone Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Autozone Inc trades at $3,072 (market cap $50.16B). The key difference: Autozone Inc is far larger — about 25.3× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | AZO | |
|---|---|---|
Market Cap | $1.98B | $50.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $4.35K |
52-Week Low | $7.64 | $2.94K |
Enterprise Value | $1.70B | $62.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
AutoZone (AZO) trades at $3,072.64, up 2.07% today, amid a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue has grown steadily to $18.94B in 2025, though net income margins are declining. The company continues aggressive share buybacks and international expansion, with a consensus price target of $3,740.
The outlook is cautiously optimistic, driven by buyback programs and commercial momentum, but risks include competitive pressures and margin compression. With 73% of analysts rating it a Buy, the stock offers value if execution aligns with expansion plans, though investors should monitor same-store sales trends and macroeconomic impacts on discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
